# ProofPilot

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proofpilot

- Industry: Software
- Headquarters: New York, US
- Website: www.proofpilot.com
- Total disclosed funding: $19M
- Latest round: Series C (Jun 26, 2024)
- Investors on record: 6

## About

Based in the US, ProofPilot, Inc. provides a robust Clinical Experience Platform that enhances patient recruitment and engagement in clinical trials, supporting pharmaceutical companies and research organizations.ProofPilot, Inc. is focused on improving clinical trial efficiency through its Clinical Experience Platform, headquartered in New York, US. The company was founded in 2014 by Chris Venezia and Matthew Amsden In September 2025, ProofPilot, Inc. acquired Lokavant, Inc. to support growth and capabilities by integrating Lokavant’s cutting-edge analytics technology.ProofPilot offers a comprehensive Clinical Experience Platform specifically designed to enhance patient recruitment and engagement in clinical trials. Their core product suite includes tools for study recruitment, patient engagement, and data analytics, facilitating seamless communication between sponsors, clinical research coordinators (CRCs), and patients. The platform ensures a fully white-labeled experience for sponsors, maintaining brand continuity and fostering trust among study participants. It integrates multiple functionalities, allowing sites and sponsors to manage recruitment, engagement, and data collection efficiently while ensuring compliance with industry regulations such as GDPR and HIPAA. ProofPilot's services cater to pharmaceutical companies and research organizations primarily in the United States, Europe, and select international markets, focusing on improving the efficiency of clinical trials and reducing associated costs by streamlining workflows.ProofPilot generates revenue through a subscription-based model tailored for pharmaceutical companies and clinical research organizations. Clients can engage with the platform through various pricing plans that encompass access to core functionalities, including recruitment tools and analytics dashboards. Each plan is structured to meet the needs of different user levels, allowing scalability based on the size and complexity of clinical studies. Revenue streams may also include partnerships with other vendors, providing additional services that enhance the ProofPilot platform capabilities. The integration of these services allows clients to effectively manage their clinical trials while benefiting from comprehensive support and continuous optimization of patient engagement strategies. In September 2025, ProofPilot, Inc. acquired Lokavant, Inc. to support growth and capabilities by integrating Lokavant’s cutting-edge analytics technology.

## Funding rounds

- Series C, Jun 26, 2024, $4.7M — Mitsui Global Investment, Sopris Venture Capital
- Series B, Apr 4, 2022, $13M — Mitsui Global Investment, Sopris Venture Capital, First Trust Capital Management, Excelra
- Seed, Nov 3, 2014, $1.9M — Cue Ball Capital, Brooklyn Bridge Ventures

## Investors

- Cue Ball Capital (https://capitalatlas.ai/funds/cue-ball-capital) — Seed
- Brooklyn Bridge Ventures (https://capitalatlas.ai/funds/brooklyn-bridge-ventures) — Seed
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series B, Series C
- Sopris Venture Capital (https://capitalatlas.ai/funds/sopris-venture-capital) — Series B, Series C
- First Trust Capital Management — Series B
- Excelra — Series B